Hologic (HOLX)
(Delayed Data from NSDQ)
$77.96 USD
+0.61 (0.79%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $77.97 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum C VGM
Price, Consensus and EPS Surprise
HOLX 77.96 +0.61(0.79%)
Will HOLX be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for HOLX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HOLX
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
Hologic (HOLX) Ascends While Market Falls: Some Facts to Note
HOLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
GE HealthCare (GEHC) Uses AI Solution to Boost Medical Imaging
QIAGEN (QGEN) Partners With IPPA to Raise TB Screening Awareness
Hologic (HOLX) Rises But Trails Market: What Investors Should Know
Other News for HOLX
Analyst Favorites With Strong Buyback Activity: Hologic Ranks As a Top Pick
Director Scott Garrett Sells 16,441 Shares of Hologic Inc (HOLX)
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
Goldman's top 25 stock picking opportunities
Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing